SCHEDULE: StepStone Group Reports 6.6% Stake in OnKure Therapeutics
Beneficial Ownership Filing
StepStone Group and its affiliates have disclosed beneficial ownership of 2,660,612 shares, representing 6.6% of OnKure Therapeutics' Class A Common Stock.
Summary
- StepStone Group LP, along with its affiliates StepStone Master G, L.P. and StepStone VC MI-G GP, LLC, has filed a Schedule 13G.
- The filing indicates beneficial ownership of 2,660,612 shares of OnKure Therapeutics, Inc. Class A Common Stock.
- This holding represents 6.6% of the total outstanding Class A Common Stock, based on 40,395,478 shares outstanding as of April 1, 2026.
- The reporting persons are investment managers and general partners organized under Delaware law.
- The filing certifies that the securities were not acquired for the purpose of influencing the control of the issuer.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it is a standard disclosure of beneficial ownership and does not provide operational or financial performance updates.
Positives
- StepStone Group's investment signifies confidence in OnKure Therapeutics' potential.
- The 6.6% stake is a notable position, suggesting a significant investment by a major financial entity.
Risks
- The filing does not detail specific risks associated with the investment or the company's operations.
Future Outlook
The filing does not contain forward-looking statements or guidance from the company. It is a disclosure of beneficial ownership.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in public companies. This filing indicates StepStone Group's strategic investment in the biotechnology sector, specifically within OnKure Therapeutics.
Stakeholder Impact
- Shareholders: The filing provides transparency regarding significant ownership by an institutional investor, which can influence market perception.
- Management: The disclosure confirms a substantial investment, potentially signaling support or increased scrutiny from a major shareholder.
Key Dates
| Date | Description |
|---|---|
| 2026-04-01 | Date as of which the number of outstanding shares of Common Stock was provided by the Issuer. |
| 2026-04-07 | Date of certification and signature for the Schedule 13G filing. |
Keywords
Schedule 13G, StepStone Group, OnKure Therapeutics, Class A Common Stock, Beneficial Ownership, Investment Management, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.